Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler Once Daily to Combivent Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent Inhalation Aerosol CFC MDI

X
Trial Profile

A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler Once Daily to Combivent Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent Inhalation Aerosol CFC MDI

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tiotropium bromide (Primary) ; Ipratropium-bromide/salbutamol
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 09 Nov 2008 Additional trial identifier EudraCT2006-000822-30 added as reported by ClinicalTrials.gov.
    • 09 Nov 2008 Trial end date changed from Mar 2008 to Oct 2007 as reported by Clinicaltrials.gov.
    • 09 Nov 2008 Actual patient number (327) added as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top